A REVIEW OF 18F – FDG PET/CT IMAGING CHARACTERISTIC IN B CELL NON HODGKIN’S LYMPHOMA AT HANOI ONCOLOGY HOSPITAL

Văn Thắng Nguyễn1,, Văn Tuynh Chu1, Tiến Công Bùi2, Công Tùng Hoàng2, Văn Thái Phạm2,3
1 Hanoi Oncology Hospital
2 Center for Traditional Medicine and Committee of Bach Mai Hospital
3 HMU

Main Article Content

Abstract

Objective: This study aimed to review 18F-FDG PET/CT imaging characteristics of B cell Non-Hodgkin’s lymphoma at Hanoi Oncology Hospital. Materials and Methods: A retrospective descriptive study was conducted on 86 newly diagnosed B cell Non Hodgkin’s lymphoma by histopathology and immunohistochemistry at Hanoi Oncology Hospital from January 2018 to December 2022. Those patients undergone 18F-FDG PET/CT scans for pre-treatment staging. Results: Among 86 B cell NHL patients, 38 female and 48 male with mean age was 58.1 ± 16.2. There were 72 patients with aggressive NHL, in which DLBCL accounted for 45.3%. According to PET/CT imaging, the highest frequency lymph nodes were cervical and abdominal lymph nodes with 65.1% and 53.5%, correspondingly. The other lymph nodes were mediastinal (34.9%), axillary (30.2%) and inguinal (22.1%). PET/CT showed 23 extranodal sites/organs, most commonly were tonsil (16.3%), spleen (9.3%), bone marrow (9.3%), stomach (8.1%), nasopharynx (7.0%). The median SUVmax of aggressive NHL was 11.3, indolent NHL was 5.4, p < 0.01. Analysis of the correlation between size and SUVmax showed rs = 0.547, p< 0.01. Conclusions: PET/CT helps to detect lesions of B cell NHL at many sites. The SUVmax value of aggressive group higher than indolent group. This study show there was a positive correlation between size and SUVmax.

Article Details

References

Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
2. Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen-Auerbach MS (2009). Comparison of CT, PET, and PET/CT for Staging of Patients with Indolent Non-Hodgkin’s Lymphoma. Mol Imaging Biol;11(4):269-274. doi:10.1007/s11307-009-0200-9
3. Nguyễn Kim Lưu, Ngô Văn Đàn, Ngô Vĩnh Điệp (2019). Đặc điểm hình ảnh 18F-FDG PET/CT và mối liên quan của giá trị hấp thu tiêu chuẩn với một số chỉ số tiên lượng của bệnh nhân u lympho ác tính không Hodgkin tại bệnh viện Quân y 103. Tạp chí Y- Dược học Quân sự;6:64-68.
4. Phạm Văn Thái, Thiều Thị Hằng, Mai Trọng Khoa và cs (2018). Đánh giá vai trò của 18F-FDG PET/CT trong chẩn đoán giai đoạn bệnh u lympho không Hodgkin. Tạp chí Ung thư học Việt Nam;5:75-79.
5. Lại Thị Thanh Thảo, Suzanne MCB Thanh Thanh, Trần Thanh Tùng và cs (2015). Ứng dụng hình ảnh PET/CT trong phân chia giai đoạn U lympho không Hodgkin tế bào B lớn lan tỏa. Tạp chí Ung thư học Việt Nam;5:124-129.
6. Ömür Ö, Baran Y, Oral A, Ceylan Y (2014). Fluorine-18 fluorodeoxyglucose PET-CT for extranodal staging of non-Hodgkin and Hodgkin lymphoma. Diagn Interv Radiol;20(2):185-192. doi:10.5152/dir.2013.13174
7. Zhang J, Wang R, Fan Y, et al (2014). [Metabolic activity measured by 18F-FDG PET/CT in newly diagnosed patients with non-Hodgkin lymphoma: correlation with immunophenotype]. Zhonghua Yi Xue Za Zhi;94(33):2576-2579.
8. Alobthani G, Romanov V, Isohashi K, et al (2018). Value of 18F-FDG PET/CT in discrimination between indolent and aggressive non-Hodgkin’s lymphoma: A study of 328 patients. Hell J Nucl Med;21(1):7-14. doi:10.1967/s002449910701
9. Mosavi F, Wassberg C, Selling J, Molin D, Ahlström H (2015). Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes. Clin Radiol;70(11):1229-1236. doi:10.1016/j.crad.2015.06.087
10. Li J, Zhao M, Yuan L, Liu Y, Ma N (2022). [Correlation and Influencing Factors of SUVmax and Ki-67 in Non-Hodgkin Lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi;30(1):136-140. doi:10.19746/j.cnki.issn.1009-2137.2022.01.022